CSS
ENTA icon

Cubist Systematic Strategies’s Enanta Pharmaceuticals ENTA Stock Holding History

Cubist Systematic Strategies’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$598K Buy
+49,983
New +$399K ﹤0.01% 2192
2025
Q1 		– Sell
-20,255
Closed -$116K – 3022
2024
Q4 		$116K Sell
20,255
-2,665
-12% -$25.6K ﹤0.01% 2686
2024
Q3 		$237K Sell
22,920
-22,430
-49% -$293K ﹤0.01% 2512
2024
Q2 		$588K Buy
45,350
+18,003
+66% +$243K ﹤0.01% 2041
2024
Q1 		$477K Sell
27,347
-55,420
-67% -$733K ﹤0.01% 2638
2023
Q4 		$779K Buy
82,767
+14,221
+21% +$133K 0.01% 2242
2023
Q3 		$766K Sell
68,546
-31,942
-32% -$514K 0.01% 2053
2023
Q2 		$2.15M Buy
100,488
+64,217
+177% +$1.89M 0.01% 1433
2023
Q1 		$1.47M Buy
36,271
+1,447
+4% +$69.1K 0.01% 1889
2022
Q4 		$1.62M Sell
34,824
-5,499
-14% -$251K 0.01% 2032
2022
Q3 		$2.09M Buy
40,323
+2,900
+8% +$169K 0.01% 1972
2022
Q2 		$1.77M Buy
37,423
+33,227
+792% +$1.8M 0.01% 1979
2022
Q1 		$299K Sell
4,196
-42,655
-91% -$2.78M ﹤0.01% 2845
2021
Q4 		$3.5M Buy
46,851
+35,438
+311% +$2.78M 0.03% 905
2021
Q3 		$648K Buy
+11,413
New +$564K 0.01% 1847
2021
Q2 		– Sell
-4,072
Closed -$201K – 2957
2021
Q1 		$201K Buy
+4,072
New +$203K ﹤0.01% 2474
2020
Q4 		– Sell
-14,316
Closed -$655K – 2592
2020
Q3 		$655K Buy
14,316
+4,397
+44% +$213K 0.01% 1581
2020
Q2 		$498K Buy
9,919
+4,211
+74% +$218K 0.01% 1592
2020
Q1 		$294K Sell
5,708
-2,313
-29% -$123K 0.01% 1532
2019
Q4 		$496K Buy
8,021
+2,433
+44% +$151K 0.01% 1560
2019
Q3 		$336K Buy
5,588
+685
+14% +$50.9K 0.01% 1497
2019
Q2 		$414K Buy
4,903
+1,175
+32% +$106K 0.01% 1606
2019
Q1 		$356K Buy
3,728
+407
+12% +$36.5K 0.01% 1398
2018
Q4 		$235K Buy
+3,321
New +$255K 0.01% 1433
2018
Q3 		– Sell
-4,661
Closed -$540K – 1939
2018
Q2 		$540K Sell
4,661
-1,189
-20% -$119K 0.03% 757
2018
Q1 		$473K Buy
5,850
+1,243
+27% +$95.7K 0.03% 828
2017
Q4 		$270K Buy
+4,607
New +$231K 0.01% 1328
2017
Q2 		– Sell
-300
Closed -$9K – 1726
2017
Q1 		$9K Buy
+300
New +$9.34K ﹤0.01% 1568

Other funds holding ENTA

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Cubist Systematic Strategies's ENTA Position: Q3 2025 in Review

Cubist Systematic Strategies opened a new position in Enanta Pharmaceuticals (ENTA) in Q3 2025: 49,983 shares worth $598K. The stake represents ﹤0.01% of the portfolio and ranks #2192 among its holdings. This is a return to the name: Cubist Systematic Strategies previously reported a position in ENTA as recently as Q4 2024.

Cubist Systematic Strategies first reported a position in ENTA in Q1 2017 and has held it in 28 quarters since. The position peaked at $3.5M in Q4 2021. 121 funds tracked by Wall St. Rank hold ENTA as of Q3 2025.

  • Cubist Systematic Strategies held 49,983 shares of Enanta Pharmaceuticals worth $598K as of Q3 2025.
  • Enanta Pharmaceuticals was a new Cubist Systematic Strategies position in Q3 2025.
  • Enanta Pharmaceuticals made up ﹤0.01% of Cubist Systematic Strategies's portfolio in Q3 2025, its #2192 holding.
  • Cubist Systematic Strategies first reported a position in Enanta Pharmaceuticals in Q1 2017 and has held it in 28 quarters since.
  • Cubist Systematic Strategies's Enanta Pharmaceuticals position peaked at $3.5M in Q4 2021.
  • 121 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q3 2025.

Based on Cubist Systematic Strategies's 13F filing for Q3 2025, filed 14 Nov 2025.